drugset / Trial / NCT01425476

Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors

NCT01425476

RandomizedParallel-groupDouble-blindPrevention

Summary

This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination with celecoxib (Celebrex, a non-steroidal anti-inflammatory drug, or NSAID), to decrease breast cancer risk by their effect on certain biological indicators (biomarkers) of breast cancer risk (called PGE2, COX-2, and 15-PGDH) and cell changes in the breast.

Timeline

Start
2008-07
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 400 mg
Subject Cholecalciferol Other / unclassified 400 iu
Subject Cholecalciferol Other / unclassified 2000 iu

Indications